Targeting PD-L1 glycosylation with monoclonal antibodies [114] or the glycosyltransferase GLT1D1 (glycosyltransferase 1 domain containing 1) [115] has been found to enhance tumor immune response in TNBC and B cell lymphoma, respectively. Here, GLT1D1 is linked to B-cell non-Hodgkin lymphoma.